| |
| |
|
| Insider
Information: |
Hasnain Faheem |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
10 |
|
| Direct
Shares |
354,230 |
|
|
Indirect Shares
|
5,296,286 |
|
|
| Direct
Value |
$6,909,111 |
|
|
|
Indirect Value
|
$4,832,190 |
|
|
| Total
Shares |
5,650,516 |
|
|
| Total
Value |
$11,741,300 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
6
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
5
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -14.3%
|
-116.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biogen Idec Inc |
BIIB |
EVP, Oncology/Rheumato... |
2008-07-09 |
25,454 |
|
0 |
Premium* |
|
|
PDL Biopharma Inc |
PDLI |
President & CEO, Direc... |
2008-10-01 |
125,000 |
2008-10-01 |
0 |
Premium* |
|
|
Somaxon Pharmaceuticals, Inc. |
SOMX |
Director |
2013-03-06 |
0 |
2012-12-31 |
65 |
Premium* |
|
|
Receptos, Inc. |
RCPT |
President & CEO, Direc... |
2015-08-27 |
0 |
|
0 |
Premium* |
|
|
Kura Oncology Inc |
KURA |
Director |
2015-04-23 |
23,983 |
|
0 |
Premium* |
|
|
Immunic Inc |
IMUX |
Director |
2018-09-13 |
4,500 |
2018-09-13 |
3,500 |
Premium* |
|
|
Forte Biosciences Inc |
FBRX |
Director |
2017-04-19 |
0 |
2019-05-30 |
245,857 |
Premium* |
|
|
Gossamer Bio Inc |
GOSS |
President & CEO, Direc... |
2024-03-27 |
120,293 |
2024-03-27 |
5,036,073 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2023-08-11 |
10,791 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
55,000 |
2021-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBUOfficer |
• – – |
2006-02-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,374 |
|
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2006-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
28,203 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2006-09-14 |
4 |
D |
$43.39 |
$271,448 |
D/D |
(6,256) |
21,947 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2006-10-02 |
4 |
AS |
$44.55 |
$501,767 |
D/D |
(11,244) |
10,793 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-02-06 |
4 |
D |
$48.94 |
$98,859 |
D/D |
(2,020) |
14,344 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,467 |
16,364 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
29,344 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,225 |
35,569 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-03-14 |
4 |
D |
$44.11 |
$98,189 |
D/D |
(2,226) |
33,343 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-05-23 |
4 |
AS |
$49.00 |
$364,854 |
D/D |
(7,446) |
25,897 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-05-23 |
4/A |
AS |
$49.00 |
$364,854 |
D/D |
(7,446) |
26,205 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-10-04 |
4 |
D |
$65.88 |
$235,521 |
D/D |
(3,575) |
23,011 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
SVP, Oncology SBU |
• – – |
2007-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,700 |
25,918 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-02-06 |
4 |
D |
$60.52 |
$122,069 |
D/D |
(2,017) |
29,435 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,467 |
31,452 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-02-12 |
4 |
D |
$60.56 |
$108,281 |
D/D |
(1,788) |
27,647 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,430 |
38,077 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-04-08 |
4 |
AS |
$63.71 |
$414,208 |
D/D |
(6,425) |
32,116 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-07-09 |
4 |
OE |
$44.24 |
$1,384,248 |
D/D |
30,175 |
62,291 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
EVP, Oncology/Rheumatology SBU |
• – – |
2008-07-09 |
4 |
AS |
$61.71 |
$2,286,605 |
D/D |
(36,837) |
25,454 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
President & CEO |
• • – |
2008-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
0 |
- |
|
| SOMX |
Somaxon Pharmaceuticals, ... |
Director |
– • – |
2010-09-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
520 |
|
- |
|
| SOMX |
Somaxon Pharmaceuticals, ... |
Director |
– • – |
2012-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
59,423 |
59,423 |
0 |
- |
|
| SOMX |
Somaxon Pharmaceuticals, ... |
Director |
– • – |
2012-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,789 |
105,212 |
0 |
- |
|
| SOMX |
Somaxon Pharmaceuticals, ... |
Director |
– • – |
2012-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
32,586 |
137,798 |
0 |
- |
|
64 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
